Rheumatoid Arthritis

Percentage of Newly Diagnosed Patients with Rheumatoid Arthritis Starting Biologic Agents who had Tuberculosis Testing

2017-2021

Percentage of Newly Diagnosed Patients with Rheumatoid Arthritis Starting Biologic Agents who had Tuberculosis Testing (N = 680)

2017-2021

The 2015 American College of Rheumatology (ACR) Guideline for the Treatment of Rheumatoid Arthritis recommends tuberculosis (TB) screening before using biologic agents to identify latent TB infection (LTBI)¹. The ACR recommends the tuberculin skin test or interferon-γ release assays as the initial test in all rheumatoid arthritis patients starting biologic agents, regardless of risk factors for LTBI. In 2017, 94.5% (156 of 165), in 2018, 89.2% (173 of 194), in 2019, 88.7% (141 of 159), in 2020, 94.4% (85 of 90), and in 2021, 100% (72 of 72) of patients had TB testing.

¹Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 2016 Jan;68(1):1-25.